Uncategorized
Vizuro and DCB Join Forces to Revolutionize Drug Discovery and Precision Medicine with Causal Generative AI
Vizuro LLC, a leading innovator in multimodal causal AI technology, and the Development Center for Biotechnology (DCB) announced the signing of a Memorandum of Understanding (MOU) to collaboratively drive innovation and growth in the biotechnology and pharmaceutical industries.
This collaboration aims to establish a next-generation AI computational platform, advancing breakthroughs in drug discovery and accelerating the implementation of precision medicine. The partnership paves the way for groundbreaking advancements in the global biotech industry.
Vizuro LLC is a pioneering provider of multimodal causal AI technology with offices in Boston, USA, and Taipei, Taiwan. The company delivers actionable AI solutions across multiple industries, serving a global clientele over the past decade. Vizuro’s partnerships span organizations of all sizes, from Fortune 100 companies to emerging startups. In 2024, Vizuro was twice recognized as an exemplary vendor by Gartner in its Hype Cycle reports for AI technologies and advanced analytics in financial services.
DCB is a key player in Taiwan’s biotech value chain, and is recognized as “the best partner in the biotech industry”. Supported by the Department of Industrial Technology, Ministry of Economic Affairs R.O.C, DCB has been focusing on cancer drug development, precision medicine, and innovative therapies. To align with the global surge in AI advancements, DCB has established the IntelliBio division to pioneer AI-driven innovations in drug discovery.
The MOU outlines collaboration in nine major areas, including:
- Small-molecule drugs
- Antibody-drug conjugates (ADC)
- Bispecific antibodies
- Antisense oligonucleotides (ASO)
- Small interfering RNA (siRNA)
- Antibody-oligonucleotide conjugates (AOC)
- Induced pluripotent stem cells (iPSC)
- CAR-NK cell therapy
- Cancer vaccines
The partnership will also collaborate on securing resources from the Ministry of Economic Affairs, R.O.C., and NVIDIA’s “Taipei-1” A+ program to boost the platform’s AI computational capabilities. This enhanced capacity will support multimodal drug discovery and accelerate the clinical application of innovative therapies. By combining their unique expertise, Vizuro and DCB aim to create next-generation biotech products and platforms, driving progress in both research and commercial ventures.
“The causal generative AI platform developed by Vizuro enables significant advancements in drug discovery. It expands potential biological pathways, enhances target discovery, repositions drugs, and generates novel drug designs while identifying biomarkers suited for specific clinical populations. By combining DCB’s extensive expertise in drug development and startup incubation with Vizuro’s capabilities in causal and generative AI technology, this collaboration represents a powerful synergy. The integration of generative AI technology makes drug discovery processes more precise and efficient. This partnership with DCB opens new opportunities in drug discovery, injecting fresh momentum into the growth of Taiwan’s biotech and pharmaceutical industries.” Yu-Feng Wei, Co-Founder and CEO of Vizuro LLC, stated.
“Generative AI technology significantly enhances the efficiency of target exploration and drug design. By collaborating with Vizuro, a leader in generative AI, DCB aims to accelerate cancer drug development. This partnership is expected to yield niche, first-in-class, or best-in-class drugs while fostering an ecosystem for academic, industrial, and research collaborations in early-stage drug discovery. The ultimate goal is to deliver innovative medicines that benefit patients worldwide “ Dr. Hsing-Jer Tsou, DCB Chairman, emphasized.
“DCB’s robust preclinical drug development capabilities, with extensive experience in small-molecule drugs, biologics, and nucleic acid therapeutics. Vizuro, with offices in Boston and Taipei, specializes in generative AI and offers actionable AI solutions across various industries. Its expertise lies in combining deep learning and causal inference to identify biological targets and simulate drug designs from multimodal data. Together, DCB and Vizuro plan to build an AI computational platform to advance drug discovery and repositioning, efficiently finding new therapeutic uses for existing drugs. This will accelerate the development of cost-effective, precise, and rapid new medicines.” Dr. Chien-Yueh Huang, DCB Deputy Executive Director, highlighted.
This collaboration marks a major leap forward in generative AI in the biotechnology and pharmaceutical sectors. It establishes a new standard for integrating AI technologies and propelling Taiwan’s biotech industry into the global market.
Media Contact:
Vizuro LLC
Finnie Lu
Head of AI Marketing
Mobile: 886-903363701
Email: [email protected]
The post Vizuro and DCB Join Forces to Revolutionize Drug Discovery and Precision Medicine with Causal Generative AI appeared first on Pinion Newswire.
Uncategorized
SCCG Partners with Osage Nation Gaming Enterprise to Enhance Interactive Gaming Operations with Managed Services
SCCG Management, a leading global advisory firm in the gaming and sports betting industry, is proud to announce its engagement by the Osage Nation Gaming Enterprise (ONGE) to assist in developing innovative, robust, player-centric solutions for sportsbook operations, online/mobile social casino, and Class II mobile on-premise gaming, designed to enhance the patron experience with diverse content and drive operational efficiency.
The ONGE, operators of seven gaming and hospitality facilities in Oklahoma, is known for providing an intimate, guest-focused gaming, service, and entertainment experience. This collaboration marks a significant step in integrating advanced technology and operational expertise to deliver innovative solutions for the evolving interactive gaming landscape.
SCCG Managed Services (SCCGMS) specializes in turnkey solutions for tribal operators to develop, optimize, and manage sports betting and interactive gaming offerings. For the ONGE, SCCGMS will assist in sourcing and implementing customized products and services tailored to their operations. This will enable patrons to enjoy casino-style games on their mobile devices while within designated areas of the casino properties. This service ensures compliance with regulatory standards while delivering a seamless and convenient gaming experience.
“Our mission is to ensure operators like the Osage Nation Gaming Enterprise can fully harness the potential of their gaming operations,” said Stephen Crystal, Founder and CEO of SCCG Management. “This partnership is about bringing cutting-edge technology and operational expertise to elevate interactive gaming experiences. We are honored to collaborate with the ONGE, a leader in tribal gaming, to pave the way for enhanced content, responsible gaming, and innovation.”
“On behalf of Osage Casinos, we are very pleased to announce our engagement of SCCG to assist us with developing these new products and services for our guests,” offered Kimberly Pearson, CEO of Osage Gaming,
About Osage Nation
The Osage Nation is the 25th largest federally recognized tribe in the United States, with a reservation spanning Osage County, Oklahoma — an area larger than the states of Delaware and Rhode Island combined. Through its seven Osage Casinos, the Nation provides vibrant entertainment, job opportunities, and economic growth for the local community. Visit Osage Website
About SCCG Managed Services
SCCG Managed Services provides comprehensive solutions for developing and enhancing sports betting and iGaming operations. From sportsbook retail and mobile platforms to compliance and risk management, SCCGMS offers the technology, talent, and expertise needed to integrate seamlessly into existing operations. SCCGMS’s ultimate mission is to ensure a smooth project transition, enabling operators to manage and maintain their gaming platforms independently. Learn more about SCCG Managed Services
ABOUT SCCG MANAGEMENT
SCCG Management is a leading advisory firm in the global gaming industry, dedicated to driving strategic growth and maximizing revenue for over 120 client partners across diverse iGaming verticals. With offices in North America, Latin America, Africa, Asia, Europe, and Brazil, our team of seasoned industry executives leverages global relationships to enhance product distribution and seize new market opportunities. With over 30 years of experience, we specialize in navigating the complexities of tribal gaming, capitalizing on emerging markets, fostering igaming innovations, managing intellectual property, facilitating mergers and acquisitions, and advancing sports wagering and entertainment ventures. iGaming Advisory and Consultancy
Stephen A. Crystal
SCCG Management
+1 702-427-9354
email us here: [email protected]
Visit us on social media:
LinkedIn
The post SCCG Partners with Osage Nation Gaming Enterprise to Enhance Interactive Gaming Operations with Managed Services appeared first on Pinion Newswire.
Uncategorized
Veos Pharmaceuticals Unveils ThymoTropin™ to Support Muscle Health and Preservation During Weight Loss and Aging Journeys
Veos Pharmaceuticals, a leading innovator with a portfolio of nearly 40 products across the EU, US, and Canada, today announced the launch of ThymoTropin, a revolutionary over-the-counter (OTC) solution for muscle growth, repair, and preservation. ThymoTropin, powered by clinically validated thymol and carvacrol, is the first product of its kind targeting myostatin regulation, a crucial mechanism for maintaining muscle mass and performance.
As part of Veos Pharma’s commitment to delivering science-backed innovations, ThymoTropin addresses the unique needs of individuals experiencing muscle loss due to aging, chronic disease, or weight management regimens, including GLP-1 treatments and calorie-restricted diets.
Filling a Critical Gap in Muscle Health
More than 50% of individuals undergoing weight loss or battling chronic illnesses face muscle loss, impacting their mobility, strength, and overall health. ThymoTropin is formulated to counteract this decline by preserving and enhancing muscle mass through its innovative dual-action mechanism:
- Clinically proven myostatin regulation for targeted muscle preservation.
- Support for lean muscle growth and endurance, validated through preclinical and clinical studies.
“At Veos Pharmaceuticals, we are committed to addressing critical health gaps with effective, science-driven solutions,” said Dr. Bassam Damaj, Executive Chairman of Veos Pharma. “ThymoTropin is a game-changer in muscle health, offering proven benefits for individuals managing muscle loss while aligning with modern health goals, including weight loss and ageing-related care.”
Clinically Backed, Patented Innovation
ThymoTropin is supported by a robust patent portfolio, including:
- US Patent No. 11,135,178: Enhancing Muscle Growth via Monoterpenes
- CA Patent No. 2,964,239: Applications of Monoterpenes in Muscle Health
- EP Patent No. 3191086: Monoterpene Formulations for Muscle Enhancement
- PT Patent No. 3191086: Monoterpenes for Myostatin Regulation
Clinical results demonstrate up to a 50% increase in muscle mass and a 37% improvement in endurance. ThymoTropin’s unique focus on myostatin regulation differentiates it from traditional protein supplements, making it a superior solution for muscle health.
Targeted Nutrition for Growing Market Needs
The global market for muscle health and repair products continues to grow, driven by increasing demand from aging populations, oncology patients, and fitness-conscious individuals. ThymoTropin directly addresses these needs by providing:
- Muscle preservation during weight loss
- Enhanced recovery and repair
- Support for aging-related muscle decline
In a competitive landscape dominated by protein supplements like Abbott’s Protality and Nestle Boost, ThymoTropin stands out with its clinically validated myostatin regulation mechanism. Unlike traditional products, ThymoTropin offers targeted efficacy without unnecessary calories or sugars, making it an ideal solution for modern health-conscious consumers.
Growing Market Opportunity and Competitive Landscape
The global muscle health and nutritional support market are projected to exceed $15 billion by 2025, driven by increasing demand from ageing populations, oncology-supportive care, and weight management solutions. Competitor products such as Abbott’s Protality and Nestle Boost have collectively generated impressive sales, with:
- Protality generates an estimated annual revenue of $300 million and a 15% market share.
- Nestle Boost® generates an estimated $500 million annually with a 25% market share.
- Traditional whey protein supplements lead with over $8 billion in annual revenue and a dominant 60% market share.
While competitor products focus on general protein supplementation, ThymoTropin sets itself apart by targeting myostatin regulation, offering a precise and effective solution for muscle growth and preservation without unnecessary calories or sugars.
Available as an Ingredient for B2B Applications
ThymoTropin is offered as a premium ingredient for business-to-business (B2B) formulations. This enables manufacturers in the health, nutrition, and functional food sectors to incorporate ThymoTropin’s proven myostatin-targeting benefits into their products, meeting growing consumer demand for advanced muscle health solutions. Veos Pharma partners with businesses to provide customized solutions and ensure seamless integration into existing product lines.
About Veos Pharmaceuticals
Headquartered in Madrid, Spain, Veos Pharmaceuticals is a global leader in health innovation with a portfolio of nearly 40 products across the EU, US, and Canada. The company specializes in OTC solutions, biostimulants, and advanced nutritional products aimed at improving quality of life. Veos Pharma’s flagship products include Ocufresh®, BioPropello, OleoSorb, VEOX-Preserv, and ThymoTropin.
For more information, contact:
Dr. Bassam Damaj
Executive Chairman
Veos Pharmaceuticals, SL
Email: [email protected]
Website: www.veospharma.com
Protality is a trademark of Abbott Laboratories. Boost® is a trademark of Nestlé
References:
www.grandviewresearch.com/industry-analysis/sports-supplement-market
Nestlé, S.A. (SWX: NESN) disclosures and Abbott Laboratories (NYSE: ABT) disclosures
Forward-Looking Statements: This press release may contain forward-looking statements that involve risks and uncertainties. Veos Pharmaceuticals assumes no obligation to update or revise these statements after the date of publication.
The post Veos Pharmaceuticals Unveils ThymoTropin™ to Support Muscle Health and Preservation During Weight Loss and Aging Journeys appeared first on Pinion Newswire.
Uncategorized
TEMPLE OF UWGEAM INC PROVIDES AID TO WILDFIRE VICTIMS IN LA
TEMPLE OF UWGEAM INC., a non-profit organization dedicated to providing humanitarian aid worldwide, is extending a helping hand to those affected by the devastating wildfires in California, As a seasoned responder to global crises, TEMPIE OF UWGEAM INC. is committed to delivering essential supplies, including food, clothing, and shelter, to those in dire need. We recognize the immense challenges faced by the affected communities and are calling on the public to join forces in supporting these individuals during their darkest hour.
As the Bible reminds us, ‘Love thy neighbor as thyself’ (Mark 12:31). In times of crisis, it is our collective responsibility to come together and provide comfort to those affected,” said Bishop Darrell Kelley, Founder of TEMPLE OF UWGEAM INC.
In addition to providing tangible support, we urge everyone to offer prayers and words of encouragement to those impacted by the wildfires. As the scripture says, “The Lord is near to the brokenhearted and saves the crushed in spirit” (Psalm 34:18).
To support UWGEAM INC.’s relief efforts, please visit our website at www.templeofuwgeam.com or call our hotline at 888-557-8883. Every donation, no matter how small, counts.
Donation Instructions:
Wiring Instructions:
Beneficiary Information: UWGEAM LLC Account Number: 131424762
Address: 1441 E Highway 316, Citra, FL 32113 Bank Name: MidFlorida Credit Union
Routing Number: 263179804
PayPal: https://www.paypal.biz/uwgeam
Cash App: $Darkel
We appreciate your generosity and support in helping us provide aid to those affected by the La wildfires.
The post TEMPLE OF UWGEAM INC PROVIDES AID TO WILDFIRE VICTIMS IN LA appeared first on Pinion Newswire.
-
Entertainment & Sports5 months ago
Rachael Sage Releases Powerful Reimagined Acoustic Album, Another Side
-
Business5 months ago
Global Academic Excellence with XI TING’s Professional Tutor Team
-
Entertainment & Sports5 months ago
From Start to Success: 40 Stories of Successful C-Suite Executives Now Available for Pre-Order
-
Politics5 months ago
Musk Claims Trump Interview Targeted by Cyber Attack
-
Entertainment & Sports5 months ago
Thousands Celebrate Lisa Vanderpump’s 7th Annual World Dog Day in West Hollywood
-
Tech5 months ago
Brazil vs. Colombia Live Updates – Live Copa America 2024
-
Entertainment & Sports5 months ago
VetStem Cell Therapy Improves Quality of Life for Dog with Hip Arthritis
-
Politics5 months ago
Germany’s ports and China: How to reconcile openness, resilience and security?